Streetbeat News

Analyst Ratings

BEAM

Credit Suisse analyst Richard Law maintains a Neutral rating on Beam Therapeutics (NASDAQ:BEAM) and raises the price target from $46 to $47.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:16 pm

OSCR

Credit Suisse analyst Jonathan Yong has maintained an Outperform rating on Oscar Health (NYSE:OSCR) and raised the price target from $7 to $8.5.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:15 pm

ZIP

ZipRecruiter reported Q2 financial results, leading to a drop in its share price. Evercore ISI downgraded the stock from Outperform to Neutral and lowered its price target from $20 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 1:08 pm

FTCI

FTC Solar, Inc. (NASDAQ:FTCI) reported Q2 revenues of $32.36 million, missing the analyst consensus of $47.38 million. Adjusted EPS of $(0.06) loss also missed the consensus of $(0.04) loss. However, revenues rose 5.3% Y/Y, driven by higher product volume. The company also announced new orders from European renewables developer Five-E and a 1-Gigawatt tracker agreement for the Cat Creek Energy and Storage Project. FTCI expects Q3 revenues of $24 million-$34 million, significantly lower than the consensus of $73.98 million.

Portfolio Pulse from Nabaparna Bhattacharya

August 09, 2023 | 1:06 pm

YELL

Yellow Corporation (NASDAQ:YELL) reported Q2 earnings per share of $(0.28), beating the analyst consensus estimate of $(0.96) by 70.83%. However, the company's quarterly sales of $1.13 billion missed the analyst consensus estimate of $1.20 billion by 6.10%. Compared to the same period last year, this represents a 124.35% decrease in earnings and a 20.87% decrease in sales.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 1:06 pm

XYL

Spruce Point Capital predicts a 30%-45% long-term downside risk to Xylem's share price. They expect Xylem to underperform the S&P 500 and the water industry as its rich multiple compresses.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 1:05 pm

XYL

Spruce Point Capital Management has released a strong sell research opinion on Xylem Inc. (NYSE:XYL), citing concerns over Xylem's recent $7.5 billion acquisition of Evoqua Water Technologies. Spruce Point believes the acquisition combines two troubled companies that will fail to deliver value for shareholders. The firm also highlighted new accounting concerns and warned that Evoqua was charged for revenue fraud by the SEC and remains under federal investigation. Spruce Point sees a 30% to 45% long-term downside risk to Xylem's share price.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 1:04 pm

ABOS

Credit Suisse analyst Judah Frommer has reiterated an 'Outperform' rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:02 pm

HRT

Credit Suisse analyst Kevin Mcveigh maintains an Outperform rating on HireRight Holdings (NYSE:HRT) but lowers the price target from $15 to $13.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:01 pm

UPS

Credit Suisse analyst Ariel Rosa has maintained a Neutral rating on United Parcel Service (UPS) and lowered the price target from $204 to $194.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:01 pm